Evidence map›Paper›PMID 40073432›Full record

ArticleCancer discovery2025

Long-Term Latency of Highly Mutated Cells in Normal Mouse Skin Is Reversed by Exposure to Tumor Promoters and Chronic Tissue Damage.

Yun Rose Li, Eve Kandyba, Kyle Halliwill, Reyno Delrosario, Quan Tran, Nora Bayani, Di Wu, Olga K Mirzoeva, Melissa Quino Reeves, S M Ashiqul Islam and 6 more

Abstract read
In one paragraph

Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yun Rose LiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0002-8077-4975
Eve KandybaHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0002-9219-5284
Kyle HalliwillHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0001-5513-4725
Reyno DelrosarioHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0009-0001-2961-372X
Quan TranHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0002-5769-3480
Nora BayaniHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0009-0008-7809-7822
Di WuHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0009-0001-7369-0220
Olga K MirzoevaHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0002-5564-1564
Melissa Quino ReevesHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0002-4886-5164
S M Ashiqul IslamDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-5686-6474
Laura RivaWellcome Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.ORCID 0000-0001-5688-4915
Erik N BergstromDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0001-7740-022X
Kavya AchantaDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0009-0004-3631-5845
John DiGiovanniDivision of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-4233-6728
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0003-3596-4515
Allan BalmainHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID 0000-0001-6549-7861

Funding

Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
PROMINENT - UCSFOT2CA278665 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2022 to 2026
$8.9M
Systems genetics analysis of tumor evolution in the mouseR35CA210018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2017 to 2026
$8.0M
Diversity Supplement to "Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis"DP5OD033424 · OD · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LI, YUN ROSE · 2022 to 2025
$2.1M
Genetic network analysis of cancer targetsU01CA176287 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2013 to 2016
$1.2M
Genetic analysis of ras mutation specificity in skin and lung cancerR01CA184510 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN · 2015 to 2017
$1.1M
PROMINENT - IRBOT2CA278668 · NCI · FUNDACIO INSTITUT DE RECERCA BIOMEDICA · PI LOPEZ-BIGAS, NURIA · 2022 to 2024
$1.0M
Single cell analysis of the evolving mutational landscape in carcinogen exposed skinR50CA251479 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANDYBA, EVE · 2020 to 2023
$397k
Examining the impact of the obesity-inflammation axis on cancer by genomic and transcriptomic profilingF32CA232635 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, YUN ROSE · 2018 to 2020
$202k
Cancer Research UK (CRUK) MUTOGRAPHSCancer Research UK (CRUK) PROMINENTCommon Fund (NIH Common Fund) 1DP5OD033424National Cancer Institute (NCI) 1OT2CA278668-01National Cancer Institute (NCI) 5K12CA001727National Cancer Institute (NCI) F32CA232635National Cancer Institute (NCI) R35CA210018National Cancer Institute (NCI) R50CA251479National Cancer Institute (NCI) RO1CA184510National Cancer Institute (NCI) UO1 CA176287NCI NIH HHS F32 CA232635NCI NIH HHS K12 CA001727NCI NIH HHS OT2 CA278665NCI NIH HHS OT2 CA278668NCI NIH HHS R01 CA184510NCI NIH HHS R35 CA210018NCI NIH HHS R50 CA251479NCI NIH HHS U01 CA176287NIH HHS DP5 OD033424
6 · The paper itself

Abstract

Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell proliferation. Initiation was proposed to be permanent, with promotion as the critical rate-limiting step for cancer development. In this study, we carried out whole-genome sequencing to demonstrate that initiated cells with thousands of mutagen-induced mutations can persist for long periods and are not removed by cell competition or by immune intervention, thus mimicking the persistence of cells with cancer driver mutations in normal human tissues. In the mouse, these cells do not give rise to tumors unless exposed to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Tissue damage and regenerative proliferation, but not normal cell turnover, consistently trigger tumor formation. Wounding, promoter treatment, and obesity enhance promotion without increasing mutational burden, supporting the possibility of future cancer prevention efforts directed at promotional risk factors. SIGNIFICANCE: Using historical skin cancer models, we reveal that mutated cells can persist without tumor formation and give rise to cancer upon exposure to tumor promoters, underscoring the importance of tumor promotion over initiation as the rate-limiting step in carcinogenesis and the need for cancer prevention strategies targeting promotional factors. See related commentary by Lim and DeGregori, p. 1090.

Indexed as

CarcinogensMutationSkinSkin NeoplasmsAnimalsDisease Models, AnimalHumansMiceTetradecanoylphorbol AcetateCarcinogensTetradecanoylphorbol Acetate

Identifiers

PMID40073432
PMCPMC12130806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.